CION Ameerpet
A stereotactic (needle) biopsy takes a tiny tumour sample through a small opening using image guidance — no wide opening of the skull. It is the safest way to get the exact diagnosis that decides your treatment.
A scan can show that there is an abnormal area in the brain. It usually cannot tell you, with certainty, exactly what that area is. Only looking at the tissue under a microscope can confirm the type of brain tumour and how it is likely to behave. A stereotactic brain biopsy is the precise, minimally invasive way to get that tissue.
"Stereotactic" means the needle is steered to a target using exact three-dimensional coordinates. Before the procedure, your MRI and CT scans are combined into a detailed map of the brain. During the procedure, a small opening — a burr hole, usually under one centimetre — is made in the skull, and a fine needle is guided along a carefully planned path to the tumour. One or more tiny tissue cores are removed. The skull is not opened widely, and the surrounding healthy brain is protected.
Modern systems use either frameless image guidance (a navigation system that tracks the needle in real time) or a lightweight stereotactic head frame. Both achieve the same goal: reaching the exact spot the team needs to sample. You may also see this described as a needle biopsy of a brain tumour — the two terms mean the same thing.
Under the World Health Organization (WHO) 2021 classification of central nervous system tumours, the diagnosis of a glioma is no longer based on how the cells look alone — it is defined by molecular markers such as IDH mutation and 1p/19q co-deletion tested on the biopsy sample. The European Association of Neuro-Oncology (EANO) and NCCN both build their treatment guidelines around these marker results. In other words, a single well-targeted biopsy now decides not just whether it is a tumour, but exactly which tumour — and which treatment fits.
A biopsy and tumour-removal surgery are not the same decision. Sometimes the goal is only to find out what the tumour is. Other times, removing the tumour will itself help — and a sample is taken during that operation. Your neuro-oncology team chooses the safest route for your situation.
A stereotactic needle biopsy is usually the right choice in these situations:
When the tumour is reachable and removing it would relieve pressure or improve outcomes, the team may instead recommend brain tumour surgery, which takes a sample and removes tumour in a single operation. Both routes are coordinated with accredited neurosurgical partners, and the choice is reviewed by CION's tumour board for every patient.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Whether a biopsy has just been advised or you already have a report, CION's neuro-oncology tumour board will review it — and arrange molecular testing on the sample — so your treatment plan is built on the right diagnosis.
Knowing what happens removes a lot of the fear. Here is the typical sequence, from planning to going home. The exact details depend on the tumour's location and your overall health, and your team will walk you through your own plan.
The neurosurgical part of the biopsy is coordinated with accredited neurosurgical partners. CION delivers your imaging, neuropathology review, molecular testing and the oncology care that follows — so you stay with one coordinated team. Speak to a CION neuro-oncologist if a biopsy has been advised and you have questions.
The value of a biopsy is not just confirming "tumour or not". The same sample is used to build the full, modern diagnosis:
A pathologist examines the tissue to identify the tumour type and assign a WHO grade (1 to 4), which describes how aggressive the cells appear. A preliminary look can sometimes be available quickly, but the full report usually takes a few days.
The same sample is then tested for molecular markers — IDH mutation, MGMT promoter methylation and 1p/19q co-deletion. Under the current WHO classification, two tumours that look identical under the microscope can be completely different diseases depending on these markers. IDH status, for example, is the single most powerful prognostic marker in glioma. MGMT methylation predicts how well a tumour responds to alkylating chemotherapy. This is why CION arranges molecular testing on the biopsy tissue as standard for malignant gliomas — it can change both the diagnosis and the recommended treatment. Molecular results usually take one to two weeks.
Modern image-guided stereotactic biopsy is highly reliable — published series generally report a diagnostic yield above 90%, meaning the sample gives a clear answer in the large majority of cases. NCCN and EANO guidelines recommend that, wherever it is safe, enough tissue is taken to allow full molecular testing — not just a basic look under the microscope — because those marker results now define the diagnosis itself.
A stereotactic biopsy is considered a low-risk procedure, but no brain procedure is completely risk-free. Being clear about the risks helps you give informed consent and know what to watch for afterwards.
After the biopsy, most patients are observed for a day, then recover at home over the following week. Your team will tell you which symptoms — such as a worsening headache, new weakness, or fever — should prompt an urgent call.
A brain biopsy result shapes everything that follows, so it is reasonable — and often valuable — to have it reviewed. A second opinion is particularly worthwhile in these situations:
CION offers a dedicated, free written second-opinion service: your imaging and pathology are re-reviewed, molecular testing is arranged on the existing sample if it has not been done, and your case is discussed by the neuro-oncology tumour board. You can also explore the full brain tumour treatment pathway or call 18002028726 to speak with the team.
Get a free written second opinion from CION's neuro-oncology tumour board — particularly valuable if molecular testing (IDH, MGMT) has not been arranged on your sample.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.A stereotactic brain biopsy is a minimally invasive way to take a small tissue sample from a brain tumour without opening the skull widely. The surgeon makes a tiny opening (a burr hole, usually under 1 cm) and guides a fine needle to the exact target using a 3-D map built from your MRI and CT scans. "Stereotactic" simply means the needle is steered by precise coordinates — modern systems use frameless image guidance or a lightweight head frame. The tissue is then examined by a pathologist to confirm the tumour type and grade. The procedure is coordinated with accredited neurosurgical partners and is the safest way to sample deep tumours.
A stereotactic needle biopsy is preferred when removing the tumour is not the immediate goal — only a diagnosis is. This happens when the tumour sits deep in the brain or near critical speech, movement or vision areas where open removal is risky; when there are multiple lesions; when the scan suggests lymphoma or infection (which are treated with medicine, not surgery); or when a patient is not fit for a long operation. If the tumour is accessible and removal would help, the team may instead recommend brain tumour surgery that takes a sample and removes tumour in one sitting.
The needle part of the procedure is short — often 30 to 60 minutes — though planning the scans, registering the image guidance and recovery add to the day. The scalp is numbed and most stereotactic biopsies are done under sedation or light general anaesthesia, so you do not feel the needle. The brain itself has no pain receptors. Many patients go home within 24 hours after a short observation period. Your team will explain whether sedation or general anaesthesia is right for you, based on the target location and your overall health.
A stereotactic biopsy is considered low-risk, but no brain procedure is risk-free. The main risk is a small bleed along the needle path; less common risks include swelling, a brief seizure, infection, or a temporary neurological symptom depending on the target area. In a small number of cases the sample is not enough to give a clear answer and a repeat is needed. Diagnostic yield with modern image guidance is high — generally above 90%. Your neurosurgical team will discuss your personal risk based on the tumour location before you consent.
A preliminary look at the tissue (a frozen-section or smear) can sometimes be available during or shortly after the procedure. The full histopathology report — confirming the exact tumour type and WHO grade — usually takes a few days. Molecular testing for markers such as IDH mutation and MGMT methylation is run on the same sample and can take one to two weeks. CION arranges these markers on the biopsy tissue because, under the 2021 WHO classification, they change both the diagnosis and the treatment plan.
A biopsy does more than confirm "tumour or not". The same tissue is tested for molecular markers — IDH mutation, MGMT promoter methylation and 1p/19q co-deletion — that decide the precise diagnosis, the likely behaviour of the tumour, and which treatment works best. Under the current World Health Organization (WHO) classification, two tumours that look identical under the microscope can be completely different diseases depending on these markers. That is why a single well-targeted biopsy, with molecular testing arranged on it, can change everything about your treatment plan.
CION delivers your diagnostic imaging, neuropathology review, molecular testing, and the medical and radiation oncology care that follows. The stereotactic neurosurgical procedure itself is coordinated with accredited neurosurgical partners, so your sample is taken safely and then read and acted on by CION's neuro-oncology tumour board. You stay with one coordinated team from scan to diagnosis to treatment — including a free written second opinion if you already have a biopsy report from elsewhere.
Disclaimer: This content is intended for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified oncologist for guidance specific to your medical condition. The information on this page is periodically reviewed and updated by CION's medical team in accordance with current clinical guidelines.
Browse our complete guide to brain tumours and brain cancer — symptoms, scans, tumour types, treatment, prognosis and life after treatment. Tap any topic to read more.